Novartis: 5-year data confirm psoriasis drug efficacy.
(CercleFinance.com) - Psoriasis drug Cosentyx has demonstrated further its efficacy and safety, providing patients a new standard of long-term care, Novartis said late Friday.
Positive 5-year efficacy and safety data from a Phase III long-term extension study confirmed the drug's profile in patients with moderate-to-severe plaque psoriasis, the company stated.
In the past, 4-year Phase III data showed Cosentyx delivered almost clear or completely clear skin in a majority of patients, Novartis added.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Positive 5-year efficacy and safety data from a Phase III long-term extension study confirmed the drug's profile in patients with moderate-to-severe plaque psoriasis, the company stated.
In the past, 4-year Phase III data showed Cosentyx delivered almost clear or completely clear skin in a majority of patients, Novartis added.
Copyright (c) 2017 CercleFinance.com. All rights reserved.